
Vertex reports long-term results for Casgevy in sickle cell and thalassaemia
Vertex Pharmaceuticals’ Casgevy (exagamglogene autotemcel) has continued to show benefits in sickle cell disease (SCD) patients for 5.5 years and in transfusion-dependent beta-thalassemia (TDT) patients for six years. Across three ongoing Phase III studies …